# US 2006/0153778 A1 · Methods and compositions for minimizing accrual of inhalable insulin in the lungs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153778 A1
- Document ID: US20060153778A1
- Status: Published application
- Kind: A1
- Application number: 11/330,427
- Filed: 2006-01-10
- Published: 2006-07-13
- Earliest claimed: 2005-01-10
- Assignees: MannKind Corporation
- Inventors: Cohava Gelber; Anders Boss
- Web page: https://patentgrep.com/patent/US20060153778A1

## CPC

- A61K 9/0075: {for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles}
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 38/28: Insulins
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Inhalable insulin compositions are provided that rapidly clear from the lungs of patients. Additionally, methods of minimizing insulin accrual after administration of an inhaled insulin composition are disclosed.

## Claims

### Claim 1

A method for minimizing insulin accrual in the lungs of a patient after the administration of an inhaled insulin comprising:
providing said inhalable insulin composition to a patient in need thereof;
administering said inhalable insulin composition to said patient's lungs; wherein said administering is performed via inhalation; and
wherein said inhaled insulin is cleared from said patient's lungs in less than approximately six hours

### Claim 2 (depends on 1)

The method according to claim 1 wherein said inhalable insulin composition is a dry powder.

### Claim 3 (depends on 1)

The method according to claim 1 wherein said providing step includes providing insulin complexed with a diketopiperazine.

### Claim 4 (depends on 3)

The method according to claim 3 wherein said diketopiperazine is fumaryl diketopiperazine.

### Claim 5 (depends on 1)

The method according to claim 1 wherein said inhaled insulin is cleared from said patient's lungs in less than approximately three hours.

### Claim 6 (depends on 1)

The method accord to claim 1 wherein a patient's lung function is not depressed on extended use of said inhaled insulin composition, wherein said patient's lung function is not impaired.

### Claim 7 (depends on 6)

The method accord to claim 6 wherein a patient's lung function is not depressed on extended use of said inhaled insulin composition, wherein said patient's lung function is not impaired relative to the same patient not receiving an inhaled insulin composition.

### Claim 8

An inhalable insulin composition comprising:
an insulin/diketopiperazine complex wherein said insulin is cleared from a patient's lungs in less than approximately six hours after inhalation.

### Claim 9 (depends on 8)

The inhalable insulin composition of claim 8 wherein said insulin is cleared from said patient's lungs in less than approximately three hours.

### Claim 10 (depends on 8)

The inhalable insulin composition of claim 8 wherein said inhalable insulin composition is a dry powder.

### Claim 11 (depends on 10)

The inhalable insulin composition of claim 10 wherein said diketopiperazine is fumaryl diketopiperazine.

### Claim 12 (depends on 8)

The inhalable insulin composition of claim 8 wherein said insulin is monomeric or dimeric.

### Claim 13 (depends on 8)

The inhalable insulin composition of claim 8 wherein said diketopiperazine is cleared from a patient's lung in less than 6 hours.

### Claim 14 (depends on 8)

The inhalable insulin composition of claim 8 wherein a patient's lung function is not depressed on extended use of said inhaled insulin composition, wherein said patient's lung function is not impaired.

### Claim 15 (depends on 14)

The inhalable insulin composition of claim 14 wherein a patient's lung function is not depressed on extended use of said inhaled insulin composition, wherein said patient's lung function is not impaired relative to the same patient not receiving an inhaled insulin composition.

### Claim 16

A method of treating diabetes comprising
providing an inhalable insulin composition to a patient in need thereof wherein extended use of said inhalable insulin composition does not impair lung function.

### Claim 17

An inhalable insulin composition useful for treating diabetes comprising:
an insulin/diketopiperazine complex wherein said inhalable insulin composition does not impair lung function.
